More is better: a multimodality approach to cancer cachexia
- PMID: 20133501
- PMCID: PMC3227946
- DOI: 10.1634/theoncologist.2010-0019
More is better: a multimodality approach to cancer cachexia
Abstract
The author comments on the findings of Mantovani et al. with combination therapy to treat cancer cachexia published in this issue of The Oncologist.
Conflict of interest statement
The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the author or independent peer reviewers.
Comment on
-
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.Oncologist. 2010;15(2):200-11. doi: 10.1634/theoncologist.2009-0153. Epub 2010 Feb 15. Oncologist. 2010. PMID: 20156909 Free PMC article. Clinical Trial.
References
-
- Jatoi A, Dakhil SR, Nguyen PL, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: Results from N00C1 from the North Central Cancer Treatment Group. Cancer. 2007;110:1396–1403. - PubMed
-
- Wiedenmann B, Malfertheiner P, Friess H, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008;6:18–25. - PubMed
-
- Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469–2476. - PubMed
-
- Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol. 2002;20:567–573. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources